| (Values in U.S. Thousands) | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 | Dec, 2010 |
| Sales | 32,390 | 10,320 | 5,350 | 86,950 | 68,550 |
| Sales Growth | +213.86% | +92.90% | -93.85% | +26.84% | +112.95% |
| Net Income | 19,670 | -16,710 | -25,280 | 42,340 | 23,070 |
| Net Income Growth | +217.71% | +33.90% | -159.71% | +83.53% | +436.30% |
Pozen Inc (POZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Its initial area of focus is migraine, where the company have built a portfolio of four product candidates through a combination of innovation and in-licensing. Its lead product candidate is MT 100, which the company is developing as an oral first-line therapy for the treatment of migraine.